Capecitabine-based treatment of a patient with a novelDPYDgenotype and complete dihydropyrimidine dehydrogenase deficiency-Reference-Cited by-同舟云学术

Capecitabine-based treatment of a patient with a novelDPYDgenotype and complete dihydropyrimidine dehydrogenase deficiency

Published:2017-09-30 Issue:2 Volume:142 Page:424-430
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Henricks Linda M.¹^ORCID,Siemerink Ester J.M.²,Rosing Hilde³,Meijer Judith⁴,Goorden Susan M.I.⁴,Polstra Abeltje M.⁴⁵,Zoetekouw Lida⁴,Cats Annemieke⁶,Schellens Jan H.M.¹⁷,van Kuilenburg André B.P.⁴

Affiliation:

1. Division of Pharmacology and Division of Clinical Pharmacology, Department of Medical Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands

2. Department of Internal Medicine; Ziekenhuis Groep Twente (ZGT); Hengelo The Netherlands

3. Department of Pharmacy and Pharmacology; The Netherlands Cancer Institute; Amsterdam The Netherlands

4. Laboratory Genetic Metabolic Diseases, Departments of Clinical Chemistry and Clinical Genetics; Academic Medical Center, University of Amsterdam; Amsterdam The Netherlands

5. Department of Clinical Genetics; VU University Medical Center; Amsterdam The Netherlands

6. Department of Gastrointestinal Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands

7. Utrecht Institute for Pharmaceutical Sciences, Utrecht University; Utrecht The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Clinical pharmacology of 5-fluorouracil;Diasio;Clin Pharmacokinet,1989

2. Population study of dihydropyrimidine dehydrogenase in cancer patients;Etienne;J Clin Oncol,1994

3. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy;Lu;Cancer Res,1993

4. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data;Meulendijks;Lancet Oncol,2015

5. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing;Caudle;Clin Pharmacol Ther,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-23

2. Is uracil enough for effective pre-emptive DPD testing?;Clinical Chemistry and Laboratory Medicine (CCLM);2024-07-19

3. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis;Clinical Chemistry and Laboratory Medicine (CCLM);2024-06-19

4. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants;JCO Precision Oncology;2024-05

5. Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities;International Journal of Biological Sciences;2024